
BEKHealth
Developed a family of R&D solutions that increases the efficiency and performance of research operations.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor investor investor investor investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 Valuation: €0.0 8.3x EV/Revenue | round | |
investor | €0.0 | round | |
* | $4.0m Valuation: $27.5m | Late VC | |
Total Funding | 000k |
USD | 2021 | 2022 | 2023 |
---|---|---|---|
Revenues | 0000 | 0000 | 0000 |
% growth | - | 276 % | 6 % |
EBITDA | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 |
EV | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
BEKHealth, founded in 2016 by Jason Baumgartner, provides a specialized software-as-a-service (SaaS) platform for the clinical research industry. The company's creation was spurred by Baumgartner's extensive experience in healthcare, including roles in genomics and consulting for major biopharmaceutical companies, where he identified a critical inefficiency in how patients were matched to clinical trials. He observed the highly manual and time-consuming processes at medical centers, which inspired him to develop a technology-driven solution to a significant industry problem.
The company's core offering is an AI-powered platform designed to streamline and accelerate clinical trial processes for research organizations, pharmaceutical companies, and contract research organizations (CROs). The business generates revenue through its integrated software suite that addresses several key areas of clinical research. This includes the BEKTRANSLATE tool for standardizing EMR data, BEK GALILEO for assessing trial feasibility, and BEK AUTORECRUITER for automating patient screening. The platform's main function is to process vast amounts of both structured and unstructured data from electronic medical records (EMRs), enabling it to identify eligible patient candidates with high precision. This capability allows clients to assess population feasibility for studies, optimize trial protocols, and significantly speed up patient recruitment.
A key feature of BEKHealth's technology is its ability to extract and analyze data from physician notes and other unstructured sources within EMRs, which traditionally are difficult to parse. This allows the system to capture up to three times more trial criteria compared to conventional methods, leading to a more comprehensive and accurate matching of patients to studies. By automating what is typically a manual chart review process, the platform helps research sites increase enrollment rates, expand their trial portfolios, and improve the diversity of trial participants. The company reports that its solution can lead to finding ten times more qualified patients and doubling the speed of enrollment. To date, BEKHealth has secured $15.7 million in funding over four rounds from investors including Hatteras Venture Partners, Boston Millennia Partners, and Excelerate Health Ventures.
Keywords: clinical trial recruitment, patient matching, EMR data processing, clinical research software, feasibility assessment, site selection, real-world evidence, healthcare AI, protocol design optimization, unstructured data extraction, patient screening automation, clinical trial technology, health data analytics, SaaS, pharmacovigilance, life sciences technology, clinical data management, research operations, patient identification, trial enrollment